http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-056310-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| filingDate | 2006-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0614f19294da7546c3292c57ca69a051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_805340423d713fcf1ebb959a1285d969 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d755463cdeb7a4ba3d9f9d402388ae26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e5f06eb410c4e78a2477b16133ba75a |
| publicationDate | 2007-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-056310-A1 |
| titleOfInvention | PURINE DERIVATIVES, PROCEDURE FOR OBTAINING, PHARMACEUTICAL COMPOSITIONS AND USES |
| abstract | The compounds of the formula I wherein X is OH or NH2, R1 is H or A, R2, R3 are in each case independently of each other, H, A, Hal, OH, OA or CN, R4 is Ar or Het1, R5, R6 are in each case, independently of each other, H or A, A is phenyl, which is not substituted or which may be mono-, di- or trisubstituted with Hal, A, OA, OH, alkenyl with 2 to 6 C atoms, alkynyl with 2 to 6 C atoms, NO2, NR5R6, CONR5R6, COOH, COOA, CN, CHO, COA, phenyl, (CH2) nHet, O (CH2) nHet, NH (CH2) nHet , O (CH2) nCyc, NH (CH2) nCyc, O (CH2) mNR5R6, NR1 (CH2) mNR5R6 and / or O (CH2) mNR1 (CH2) mOR1, Het1 is a mono- or biblical aromatic heterocycle with 1 to 4 atoms of N, OY / or S, which is not substituted or which may be mono-, di- or trisubstituted with Hal, A, OA, OH, alkenyl with 2 to 6 C atoms, alkynyl with 2 to 6 C atoms , NO2, NR5R6, CONR5R6, COOH, COOA, CN, CHO, COA, phenyl, (CH2) nHet, O (CH2) nHet, O (CH2) nCyc, NH (CH2) nCyc, O (CH2) mNR5r6, NR1 ( CH2) mNR5R6 and / or O (CH2) mNR1 (CH2) mOR1, Het is a heterocycle mo no- or bicyclic saturated, unsaturated or aromatic with 1 to 4 atoms of N, O and / or S, which may not be substituted or which may be mono-, di- or trisubstituted with Hal, A, OA, phenyl, COOA, CN and / or carbonyl oxygen (= O), A is alkyl with 1 to 10 C atoms, where also 1-7 H atoms can be replaced by F and / or chlorine, Cyc is cycloalkyl with 3 to 7 atoms of C, Hal is F, Cl, Br or I, n is 0, 1, 2, 3 or 4, m is 1, 2, 3 or 4, as well as its derivatives, solvates, salts, tautomers and stereoisomers of pharmaceutical utility , including their mixtures in all proportions. They are inhibitors of tyrosine kinases, especially TIE-2, and Raf-kinases, and can be used, for example, for the treatment of tumors. Process of preparation of said compounds and pharmaceutical compositions comprising them. |
| priorityDate | 2005-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.